I

Instylla

Interventional radiology embolic device developer

Overview

Instylla develops medical devices for interventional radiology, focusing on liquid embolic agents. Its flagship Embrace HES uses two low-viscosity liquid precursors that, when injected, form a PEG hydrogel to permanently block blood flow, enabling embolization of hypervascular tumors and control of arterial bleeding; the system is solvent-free, deeply penetrates the tumor bed, and provides imaging-friendly follow-up. The company differentiates itself with a solvent-free, in situ forming hydrogel that creates durable occlusion and is backed by clinical data, including FDA PMA approval in 2025, and it is also developing Tembo, a bioresorbable embolic system. Instylla aims to bring advanced embolization solutions to interventional radiologists for oncology and hemorrhage control and to broaden commercialization of next-generation embolic technologies.

Work here?Claim your company

About Instylla

Simplify's Rating
Not yet rated

We're working on gathering enough insights on this company, check back soon!

Industries

Industrial & ManufacturingHealthcare

Company Size

51-200

Company Stage

Late Stage VC

Total Funding

$63.5M

Headquarters

Bedford, MA

Founded

2017

Get referred to Instylla

See people who can refer or advise you

Funding

Total Funding

$63.5M

Above

Industry Average

Funded Over

3 Rounds

Late VC funding comparison data is currently unavailable. We're working to provide this information soon!
Late VC Funding Comparison Coming Soon

Growth & Insights

6 month growth

5%

1 year growth

47%

2 year growth

70%

Recently Posted Jobs

Sign up to get curated job recommendations

Instylla is Hiring for 5 Jobs on Simplify!

Find jobs on Simplify and start your career today

Don't see your dream role? Check out thousands of other roles on Simplify.Browse all jobs